Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Laurent Bellon is active.

Publication


Featured researches published by Laurent Bellon.


The Journal of Clinical Pharmacology | 2000

Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers

Jennifer A. Sandberg; Vann P. Parker; Karin S. Blanchard; David Sweedler; James A. Powell; Arlee Kachensky; Laurent Bellon; Nassim Usman; Thomas Rossing; Ernest C. Borden; Lawrence M. Blatt

The pharmacokinetics and tolerability of a chemically stabilized synthetic ribozyme (ANGIOZYME™) targeting the Flt‐1 VEGF receptor mRNA were evaluated in healthy volunteers. In a placebo‐controlled, single‐dose escalation study, ribozyme was administered as a 4‐hour IV infusion of 10 or 30 mg/m2 or as a SC bolus of 20 mg/m2. Peak ribozyme plasma concentrations of 1.5 and 3.8 μg/mL were observed after the 10 and 30 mg/m2 IV infusions, respectively. When normalized to dose, AUC values as well as peak concentrations increased proportionally as the dose was increased from 10 to 30 mg/m2. Peak concentrations of 0.9 μg/mL were observed approximately 3.25 hours after a 20 mg/m2 SC bolus of ribozyme. The dose‐normalized AUCs obtained after SC dosing were compared to the mean dose‐normalized AUC after IV dosing to estimate an absolute SC bioavailability (f) of approximately 69%. An average elimination half‐life of 28 to 40 minutes was observed after IV administration, which increased to 209 minutes after SC administration. Only 4 of 12 reported adverse events were possibly related to administration of ribozyme (headache and somnolence). Thus, ribozyme administration was well tolerated after a single 4‐hour IV infusion of up to 30 mg/m2 or a single SC bolus of 20 mg/m2.


Nucleosides, Nucleotides & Nucleic Acids | 1992

Efficient Synthesis of 4-Thio-D-ribofuranose and Some 4′-Thioribonucleosides

Laurent Bellon; J. L. Barascut; Jean-Louis Imbach

Abstract A synthetic pathway to reach easily the 4-thio-D-ribofuranose is described. Some corresponding pyrimidine α and β 4′-thioribonucleosides have been synthesized and evaluated as antiviral agents against various viruses.


Nucleosides, Nucleotides & Nucleic Acids | 1997

Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes

Laurent Bellon; Christopher T. Workman; Carolyn Gonzalez; Francine E. Wincott

Abstract A convergent approach, based on the reductive amination of 3′-phospho-glycaldehyde-ribozyme 3 with 5′-aminohexyLribozyme 1 generated an amino-linked ribozyme 4 in good yields. Catalytic activity of the cross-linked ribozyme is discussed.


Nucleosides, Nucleotides & Nucleic Acids | 1995

4′-Thio-β-D-oligoribonucleotides: Nuclease Resistance and Hydrogen Bonding Properties

C. Leydier; Laurent Bellon; J. L. Barascut; Jean-Louis Imbach

Abstract The syntheses and the study of nuclease resistance and hydrogen bonding of modified oligoribonucleotides, i.e. 4′-thio-β-D-oligoribonucleotides (4′-S-RNA), are reported.


Nucleosides, Nucleotides & Nucleic Acids | 1993

A reinvestigation of the synthesis of 4-thio-pentofuranosides for further nucleosidic synthesis

Laurent Bellon; C. Leydier; J. L. Barascut; Jean-Louis Imbach

Abstract We demonstrate that the procedure of Huang and Hui(4), applied to the D-ribose and involving Ph3P/I2/Imidazole reagent system do not lead to the desired 4-thio-D-ribofuranoside derivative but gives its diastereoisomer 4-thio-L-lyxofuranoside derivative 4


Archive | 1999

Nucleic acid molecules with novel chemical compositions capable of modulating gene expression

James Thompson; Leonid Beigelman; James Mcswiggen; Alexander Karpeisky; Laurent Bellon; Mark Reynolds; Michael Zwick; Thale Jarvis; Tod M. Woolf; Peter Haeberli; Jasenka Matulic-Adamic


Hepatology | 2000

Inhibition of hepatitis C virus (HCV)‐RNA–dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

Dennis Macejak; Kristi Jensen; Sharon Jamison; Kristal Domenico; Elisabeth Roberts; Nilabh Chaudhary; Ira von Carlowitz; Laurent Bellon; Myron J. Tong; Andrew Conrad; Pamela Pavco; Lawrence M. Blatt


Archive | 1999

Deprotection of RNA

Laurent Bellon; Christopher T. Workman


Hepatology | 2000

Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice

Patrice Lee; M P H Lawrence Blatt Dr.; Karin Blanchard; Karyn S. Bouhana; Pamela Pavco; Laurent Bellon; Jennifer A. Sandberg


Journal of the American Chemical Society | 1996

OLIGONUCLEOTIDE MIMICS FOR ANTISENSE THERAPEUTICS : SOLUTION PHASE AND AUTOMATED SOLID-SUPPORT SYNTHESIS OF MMI LINKED OLIGOMERS

François Morvan; Yogesh S. Sanghvi; Michel Perbost; Jean-Jacques Vasseur; Laurent Bellon

Collaboration


Dive into the Laurent Bellon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher T. Workman

Technical University of Denmark

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. L. Barascut

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge